AU2006330199A1 - Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof - Google Patents

Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof Download PDF

Info

Publication number
AU2006330199A1
AU2006330199A1 AU2006330199A AU2006330199A AU2006330199A1 AU 2006330199 A1 AU2006330199 A1 AU 2006330199A1 AU 2006330199 A AU2006330199 A AU 2006330199A AU 2006330199 A AU2006330199 A AU 2006330199A AU 2006330199 A1 AU2006330199 A1 AU 2006330199A1
Authority
AU
Australia
Prior art keywords
complex formulation
amlodipine
simvastatin
film layer
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006330199A
Other languages
English (en)
Inventor
Moon Hyuk Chi
Yong Il Kim
Jong Soo Woo
Hong Gi Yi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of AU2006330199A1 publication Critical patent/AU2006330199A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2006330199A 2005-12-27 2006-12-22 Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof Abandoned AU2006330199A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020050130531A KR100742432B1 (ko) 2005-12-27 2005-12-27 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR10-2005-0130531 2005-12-27
PCT/KR2006/005658 WO2007075009A1 (en) 2005-12-27 2006-12-22 Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof

Publications (1)

Publication Number Publication Date
AU2006330199A1 true AU2006330199A1 (en) 2007-07-05

Family

ID=38218207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006330199A Abandoned AU2006330199A1 (en) 2005-12-27 2006-12-22 Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof

Country Status (11)

Country Link
US (1) US20090005425A1 (enExample)
EP (1) EP1978956A4 (enExample)
JP (1) JP2009521526A (enExample)
KR (1) KR100742432B1 (enExample)
CN (1) CN101346140A (enExample)
AU (1) AU2006330199A1 (enExample)
BR (1) BRPI0620790A2 (enExample)
CA (1) CA2634639A1 (enExample)
IL (1) IL192148A0 (enExample)
RU (1) RU2008130873A (enExample)
WO (1) WO2007075009A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY173823A (en) * 2009-01-23 2020-02-24 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
WO2010107081A1 (ja) * 2009-03-19 2010-09-23 第一三共株式会社 包装により安定保存された固形製剤
CN101836981B (zh) * 2009-12-01 2011-12-14 严洁 复方缬沙坦苯磺酸氨氯地平药物组合物及其制备方法
WO2011112993A2 (en) 2010-03-11 2011-09-15 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
BR112014003529A2 (pt) * 2011-08-15 2017-03-14 Technion Res & Dev Foundation combinações de corroles e estatinas
WO2014058046A1 (ja) * 2012-10-12 2014-04-17 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤
KR20200009101A (ko) 2017-10-17 2020-01-29 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
KR20190043076A (ko) 2017-10-17 2019-04-25 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
KR102306888B1 (ko) 2019-11-25 2021-09-29 성균관대학교산학협력단 구멍쇠미역으로부터 분리된 신규 화합물을 유효성분으로 포함하는 동맥경화 예방 및 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ502283A (en) 1997-08-29 2002-05-31 Pfizer Prod Inc Cardiovascular therapy comprising amlodipine and a statin compound in amounts that are synergistically effective
US20030092745A1 (en) 2000-02-25 2003-05-15 Pfizer Inc. Combination therapy
EP1314425A4 (en) 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
DE10224612A1 (de) * 2002-06-04 2003-12-24 Lohmann Therapie Syst Lts Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung
BRPI0407038A (pt) 2003-01-27 2006-01-17 Hanmi Pharm Ind Co Ltd Camsilato de amlodipina amorfo estável, processo para a preparação do mesmo e composição para administração oral deste
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법

Also Published As

Publication number Publication date
CN101346140A (zh) 2009-01-14
US20090005425A1 (en) 2009-01-01
BRPI0620790A2 (pt) 2011-11-22
CA2634639A1 (en) 2007-07-05
RU2008130873A (ru) 2010-02-10
EP1978956A1 (en) 2008-10-15
KR100742432B1 (ko) 2007-07-24
WO2007075009A1 (en) 2007-07-05
KR20070068658A (ko) 2007-07-02
EP1978956A4 (en) 2009-08-19
IL192148A0 (en) 2009-08-03
JP2009521526A (ja) 2009-06-04

Similar Documents

Publication Publication Date Title
AU2010201739B2 (en) A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor
KR100582347B1 (ko) 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
US7772273B2 (en) Stabilized atorvastatin
US20050239884A1 (en) Compositions comprising hmg-coa reductase inhibitor
CA2588216A1 (en) Stable atorvastatin formulations
AU2006330199A1 (en) Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof
US20080038332A1 (en) Stable pharmaceutical formulation comprising atorvastatin calcium
EP3833335B1 (en) Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate
CA2621134C (en) Pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
WO2008082124A1 (en) Stabilized pharmaceutical drug of atorvastatin
EP4566591A1 (en) Solid pharmaceutical dosage form comprising ezetimibe and pitavastatin
HK1128413A (en) Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof
MX2008007383A (en) Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof
RU2850454C9 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОРЫ HMG-CoA РЕДУКТАЗЫ И ФЕНОФИБРАТ
RU2850454C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОРЫ HMG-CoA РЕДУКТАЗЫ И ФЕНОФИБРАТ
US20190070167A1 (en) Pitavastatin containing preparation and method for producing same
KR20090048023A (ko) 암로디핀 베실레이트와 아토르바스타틴 칼슘을 함유하는경구용 복합제제
WO2008102379A1 (en) Stable sustained release formulations of fluvastatin
US20090182053A1 (en) Fenofibric acid amorphous dispersion; method of making; and method of use thereof
HK1111903A (en) Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same
HK1216079B (en) Complex formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application